Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1525

1.

Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.

Kim JJ, Wright TC, Goldie SJ.

JAMA. 2002 May 8;287(18):2382-90.

PMID:
11988059
[PubMed - indexed for MEDLINE]
2.

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group.

J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.

PMID:
16418511
[PubMed - indexed for MEDLINE]
Free Article
3.

Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.

Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC.

JAMA. 2001 Jun 27;285(24):3107-15. Erratum in: JAMA 2001 Sep 5;286(9):1026.

PMID:
11427139
[PubMed - indexed for MEDLINE]
4.

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.

JAMA. 2002 Oct 9;288(14):1749-57.

PMID:
12365959
[PubMed - indexed for MEDLINE]
5.

Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden.

Ostensson E, Fröberg M, Hjerpe A, Zethraeus N, Andersson S.

Acta Obstet Gynecol Scand. 2010 Oct;89(10):1316-25. doi: 10.3109/00016349.2010.512066. Erratum in: Acta Obstet Gynecol Scand. 2010 Nov;89(11):1497.

PMID:
20846064
[PubMed - indexed for MEDLINE]
6.

Benefits and costs of using HPV testing to screen for cervical cancer.

Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K.

JAMA. 2002 May 8;287(18):2372-81.

PMID:
11988058
[PubMed - indexed for MEDLINE]
7.

Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.

Goldie SJ, Kim JJ, Wright TC.

Obstet Gynecol. 2004 Apr;103(4):619-31.

PMID:
15051550
[PubMed - indexed for MEDLINE]
8.

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

Kim JJ, Wright TC, Goldie SJ.

J Natl Cancer Inst. 2005 Jun 15;97(12):888-95.

PMID:
15956650
[PubMed - indexed for MEDLINE]
Free Article
9.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
[PubMed - indexed for MEDLINE]
Free Article
10.

The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.

Cox JT; American Society for Colposcopy and Cervical Pathology.

Arch Pathol Lab Med. 2003 Aug;127(8):950-8.

PMID:
12952506
[PubMed - indexed for MEDLINE]
11.

Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.

Mandelblatt JS, Lawrence WF, Gaffikin L, Limpahayom KK, Lumbiganon P, Warakamin S, King J, Yi B, Ringers P, Blumenthal PD.

J Natl Cancer Inst. 2002 Oct 2;94(19):1469-83.

PMID:
12359856
[PubMed - indexed for MEDLINE]
Free Article
12.

Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.

Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA.

JAMA. 1999 May 5;281(17):1605-10.

PMID:
10235153
[PubMed - indexed for MEDLINE]
13.

Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.

Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C.

Gynecol Oncol. 2009 Feb;112(2):377-83. doi: 10.1016/j.ygyno.2008.08.030. Epub 2008 Dec 11.

PMID:
19081611
[PubMed - indexed for MEDLINE]
14.

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

Kulasingam SL, Myers ER.

JAMA. 2003 Aug 13;290(6):781-9.

PMID:
12915431
[PubMed - indexed for MEDLINE]
15.

Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.

Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM.

Am J Med. 2001 Aug;111(2):140-9.

PMID:
11498068
[PubMed - indexed for MEDLINE]
16.
17.

ASC-US and HPV testing in women aged 40 years and over.

Bruner KS, Davey DD.

Diagn Cytopathol. 2004 Nov;31(5):358-61.

PMID:
15468129
[PubMed - indexed for MEDLINE]
18.

Economic evaluation of strategies for managing women with equivocal cytological results in Brazil.

Vanni T, Legood R, Franco EL, Villa LL, Luz PM, Schwartsmann G.

Int J Cancer. 2011 Aug 1;129(3):671-9. doi: 10.1002/ijc.25708. Epub 2010 Nov 12.

PMID:
20886598
[PubMed - indexed for MEDLINE]
19.

Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance.

ASCUS-LSIL Traige Study (ALTS) Group.

Am J Obstet Gynecol. 2003 Jun;188(6):1383-92.

PMID:
12824967
[PubMed - indexed for MEDLINE]
20.

Screening for cervical cancer: new alternatives and research.

Lörincz AT.

Salud Publica Mex. 2003;45 Suppl 3:S376-87. Review.

PMID:
14746031
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk